Piper Sandler analyst Jessica Tassan lowered the firm’s price target on Tabula Rasa HealthCare to $4 from $6 and keeps a Neutral rating on the shares. The company raised its fiscal 2022 revenue guidance on a Q3 sales beat but its operating losses widened considerably, Tassan tells investors in a research note. The analyst says questions about revenue mix and margin trends keep her on the sidelines.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRHC: